Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580440 | 0.74 | SLC6A2 (0.42) | CHRM3CHRM4OPRM1CHRM1CHRM2 | |
| SCHEMBL30997648 | 0.74 | SLC6A2 (0.42) | CHRM3CHRM4OPRM1CHRM1CHRM2 | |
| SCHEMBL30997628 | 0.72 | HRH3 (0.41) | HRH3CHRM3CHRM4TDP1 | |
| SCHEMBL30997610 | 0.71 | CHRM3 (0.35) | HRH3CHRM3CHRM1CHRM2TDP1 | |
| SCHEMBL26241152 | 0.71 | OPRM1 (0.64) | HRH3CHRM3OPRM1CHRM1CHRM2 | |
| SCHEMBL12049585 | 0.68 | CARM1 (0.49) | HRH3CHRM3CHRM4TDP1L3MBTL1 | |
| SCHEMBL11773404 | 0.67 | CHRM2 (0.53) | HRH3CHRM4OPRM1CHRM2CHRM5 | |
| SCHEMBL23889648 | 0.66 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL18390335 | 0.66 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL30730934 | 0.66 | ACHE (0.42) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | HRH3 3166/4885CHRM3 4882/4885CHRM4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.